Lung non-small cell carcinoma Trials in Buffalo, United States
Conditions / Lung non-small cell carcinoma / Buffalo, United States
Lung non-small cell carcinoma is a medical condition with active clinical research programs worldwide.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04214262 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING | — |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | RECRUITING | — |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | SUSPENDED | PHASE2/PHASE3 |
| NCT04298606 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | RECRUITING | EARLY_PHASE1 |
| NCT05292521 | Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer | RECRUITING | NA |
| NCT02955290 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer | NOT_YET_RECRUITING | PHASE2 |
| NCT04073745 | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | ACTIVE_NOT_RECRUITING | PHASE2 |